Principal Analyst, Datamonitor Healthcare
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 15 years. She is a senior pharma consultant with Informa Pharma Custom Intelligence, where she works with pharma and biotech clients on disease landscaping and market opportunity assessments, building on her expertise in searching and mining Informa Pharma’s portfolio of pharmaceutical intelligence solutions. Amanda has been with Informa since 2005 (through the acquisitions of Elsevier Business Intelligence and Windhover Information). Prior to joining the consulting team, she was a Principal Analyst with Datamonitor Healthcare, where she identified and highlighted trends in corporate strategy and deal making across various markets, including regenerative medicine and immuno-oncology. Prior to Datamonitor Healthcare, Amanda was a deals analyst and later the research manager for Informa Pharma biopharma and medtech deals database. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Latest From Amanda Micklus
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.
Device financing during 2019’s final quarter totaled $1.6bn, a substantial decrease from Q3’s $4.05bn. Merger and acquisition activity, almost doubled from the previous quarter reaching $6.1bn; Stryker’s 4.7bn takeover of Wright Medical was the only billion-dollar transaction. Financings by diagnostics/research players totaled $1.3bn (the lowest quarter of the year) and eight companies were acquired, five of which together were valued at $981m.
Nurix and Sanofi signed a $2.55bn deal using DELigase DNA-encoded libraries to targeted protein degradation therapies for the three targets. Lilly enhanced its immunology pipeline with the $1.1bn takeover of Dermina and its atopic dermatitis antibody lebrikizumab. Biopharma financing was slightly up, while device funding somewhat decreased.